ifx-hu2.0
Vaccineexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Aug 31, 2018 (NCT03655756)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06947928 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2025 | Morphogenesis, Inc., University of South Florida |
| NCT06940440 | Phase 1 | Oct 31, 2025 | Morphogenesis, Inc., University of South Florida |
| NCT04925713 | Phase 1 | Jun 10, 2021 | Morphogenesis, Inc. |
| NCT04160065 | Phase 1 | Nov 30, 2019 | Morphogenesis, Inc., University of South Florida |
| NCT03655756 | Early Phase 1 (Phase 1) | Aug 31, 2018 | Morphogenesis, Inc., University of South Florida |
| NCT04853602 | N/A | — | Morphogenesis, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Morphogenesis, Inc. | For profit | 6 | 6 | 3 | 2018 |
| University of South Florida | Academic/Hospital | 4 | 0 | 2 | 2018 |
2 organizations
Page 1 / 1